Nuclear Medicine Radioisotopes Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Nuclear Medicine Radioisotopes Market is segmented by Type of Radioisotope, Application, and Geography

Market Snapshot

automotive navigation system
Study Period:

2018 - 2026

Base Year:


Fastest Growing Market:

Asia Pacific

Largest Market:

North America


11.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Increasing cases of cancer and cardiac ailments are the major drivers for the nuclear medicine radioisotopes market. Nuclear medicine has a huge potential in treating cancer and cardiac diseases. Growth of medical imaging is an opportunity for the growth of the nuclear medicine radioisotope market, as both markets are correlated. Radiopharmaceuticals are approved by the Food and Drug Administration (FDA) as either drugs or biologics. They meet the statutory definition of drugs under Section 1861(t) of the Social Security Act because they either are included in the various drug compendia or recognized by hospital medical staff as drugs. Historically, nuclear medicine has been well established as a therapeutic modality for thyroid cancer, Graves’ disease, hyperthyroidism, and bone pain palliation, associated with skeletal metastasis. Hence, the broadening applications of radioisotopes are expected to propel market growth.

Scope of the Report

As per the scope of the report, medical radioisotopes are defined as safe radioactive substances that are primarily used in the diagnosis of medical conditions. These radioisotopes, used in a diagnosis, emit gamma rays of energy that are sufficient to escape from the body. The rays also have a short half-life, which is apt, since the rays can decay as soon as the imaging is completed.

Type of Radioisotopes
Technetium-99m (Tc-99m)
Thallium-201 (Tl-201)
Iodine (I-123)
Rubidium-82 (Rb-82)
Iodine-131 (I-131)
Lutetium-177 (Lu-177)
Radium-223 (Ra-223) and Alpharadin
Actinium-225 (Ac-225)
Other Types of Radioisotopes
Other Applications
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oncology Segment is Expected to Exhibit Fastest Growth Rate over the Forecast Period

Radiotherapy can be used to treat various medical conditions, especially cancer, using radiation to weaken or destroy particular targeted cells. PET, which is a precise technique, uses isotopes produced in a cyclotron. It is highly used for a clinical role in oncology, with fluorine-18 as the tracer, and it is proven to be the most accurate non-invasive method of detecting and evaluating most cancers. A new field for cancer treatment is targeted alpha therapy (TAT) or alpha radio-immunotherapy, especially for the control of dispersed cancers. Nuclear medicine is proven effective in oncology in several roles, spanning the course of the disease, including the characterization of a mass, staging, restaging, and monitoring of therapeutic response. Hence, owing to these associated factors, the oncology segment is expected to exhibit the fastest growth rate.

Picture3Nuclear Medicine Radioisotopes Market.png

To understand key trends, Download Sample Report

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America captured the largest market share in the nuclear medicine radioisotopes market. The United States was the largest contributor to the revenue of North America and is expected to retain its dominance owing to the higher procedural volume and increasing adoption of the nuclear medicine isotopes for various therapeutic applications. Bone scintigraphy is the next most common nuclear medicine procedure performed in the United States, but it represents only 17% of procedures. The volume of PET procedures in the United States is approximately 1.5 million per year. Oncology accounts for more than 90% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 4% each. Canada is the largest producer of Technetium-99m. Due to the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. 80% of the nuclear medicine market is driven by Tc-99m in various diagnostic procedures and treatments. Considering these factors associated with the United States and Canada, the North American market is expected to experience accelerated growth rates and market dominance.

Picture1Nuclear Medicine Radioisotopes Market.png

To understand geography trends, Download Sample Report

Competitive Landscape

There is high competition among the players of the global nuclear medicine radioisotopes market. However, this competition is not by virtue of competitive pricing or product differentiation. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. GE Healthcare,NTP Radioisotopes SOC Ltd, Nordion (Canada) Inc., Siemens Healthcare, and Positron Corp. are some of the major players in the nuclear medicine radioisotopes market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Cancer and Cardiac Disorders

      2. 4.2.2 Widening Applications of Nuclear Medicine

      3. 4.2.3 Increasing SPECT and PET Applications

      4. 4.2.4 Increasing Patient Awareness on Radiation and Radiation Therapy

    3. 4.3 Market Restraints

      1. 4.3.1 Reimbursement Complications

      2. 4.3.2 Regulatory Issues

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 Type of Radioisotopes

      1. 5.1.1 Technetium-99m (Tc-99m)

      2. 5.1.2 Thallium-201 (Tl-201)

      3. 5.1.3 Iodine (I-123)

      4. 5.1.4 Fluorine-18

      5. 5.1.5 Rubidium-82 (Rb-82)

      6. 5.1.6 Iodine-131 (I-131)

      7. 5.1.7 Lutetium-177 (Lu-177)

      8. 5.1.8 Radium-223 (Ra-223) and Alpharadin

      9. 5.1.9 Actinium-225 (Ac-225)

      10. 5.1.10 Other Types of Radioisotopes

    2. 5.2 Application

      1. 5.2.1 Oncology

      2. 5.2.2 Cardiology

      3. 5.2.3 Thyroid

      4. 5.2.4 Neurology

      5. 5.2.5 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Rest of the World


    1. 6.1 Company Profiles

      1. 6.1.1 Bayer AG

      2. 6.1.2 Bracco SpA

      3. 6.1.3 Cardinal Health Inc.

      4. 6.1.4 China Isotope & Radiation Corporation (CIRC)

      5. 6.1.5 Curium

      6. 6.1.6 Lantheus Medical Imaging Inc.

      7. 6.1.7 GE Healthcare

      8. 6.1.8 NTP Radioisotopes SOC Ltd

      9. 6.1.9 Fujifilm Holdings Corporation

      10. 6.1.10 Sotera Health (Nordion Inc.)

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Nuclear Medicine Radioisotopes Market market is studied from 2018 - 2026.

The Nuclear Medicine Radioisotopes Market is growing at a CAGR of 11.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

  • GE Healthcare
  • NTP Radioisotopes SOC Ltd
  • Nordion (Canada) Inc.
  • Cardinal Health, Inc.
  • Bayer AG

Are the major companies operating in Nuclear Medicine Radioisotopes Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!